Merck Sharp & Dohme LLC $MRK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS193
PHASE 3 / 2-3107
RECRUITING100
READOUTS ≤12 MONTHS35
READOUT SLIPPED >6 MO31%
Delay Index: of 144 active trials registered more than a year ago, 45 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Merck Sharp & Dohme LLC on the live radar map → 📅 $MRK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| pembrolizumab NCT02362594 |
P3 | Active, not recruiting | Melanoma | 1019 | 2018-01-08 (-4 mo) |
| Pembrolizumab NCT03553836 |
P3 | Active, not recruiting | Melanoma | 976 | 2021-06-21 (-16 mo) |
| Pembrolizumab NCT03425643 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 797 | 2023-07-10 (-6 mo) |
| Belzutifan NCT04195750 |
P3 | Active, not recruiting | Carcinoma, Renal Cell | 755 | 2024-04-15 (-17 mo) |
| Pembrolizumab/Vibostolimab Co-Formulation NCT05224141 |
P3 | Active, not recruiting | Small Cell Lung Carcinoma | 460 | 2024-06-04 (-11 mo) |
| Pembrolizumab Formulated with Berahyaluronidase Alfa NCT05722015 |
P3 | Active, not recruiting | Metastatic Non-small Cell Lung Cancer | 377 | 2024-07-12 (-2 mo) |
| Pembrolizumab 200 mg NCT03765918 |
P3 | Active, not recruiting | Head and Neck Neoplasms | 714 | 2024-07-25 (+18 mo) |
| ART NCT05631093 |
P3 | Active, not recruiting | HIV-1 Infection | 553 | 2024-10-10 |
| DOR/ISL NCT05630755 |
P3 | Active, not recruiting | HIV-1 Infection | 514 | 2024-10-25 (+1 mo) |
| Pembrolizumab Formulated with Berahyaluronidase Alfa NCT06212752 |
P3 | Active, not recruiting | Metastatic Non-small Cell Lung Cancer | 39 | 2024-11-06 (+1 mo) |
| Pembrolizumab NCT05116189 |
P3 | Active, not recruiting | Ovarian Cancer; Carcinoma, Ovarian Epithelial | 643 | 2025-03-05 (-4 mo) |
| Pembrolizumab (+) Berahyaluronidase alfa NCT06099782 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer; Renal Cell Carcinoma | 147 | 2025-04-09 (+1 mo) |
| Pembrolizumab NCT03924895 |
P3 | Active, not recruiting | Urinary Bladder Cancer, Muscle-invasive | 595 | 2025-06-06 (+4 mo) |
| Olaparib NCT03742895 |
P2 | Active, not recruiting | Advanced Solid Neoplasms | 329 | 2025-08-12 (+27 mo) |
| DOR/ISL NCT05705349 |
P3 | Active, not recruiting | HIV-1 Infection | 537 | 2025-10-13 (+7 mo) |
| DOR/ISL NCT05766501 |
P3 | Active, not recruiting | HIV Infection | 641 | 2025-10-16 (-3 mo) |
| KEYNOTE-B15 NCT04700124 |
P3 | Active, not recruiting | Bladder Cancer | 808 | 2025-10-27 (-2 mo) |
| Belzutifan NCT04586231 |
P3 | Active, not recruiting | Carcinoma, Renal Cell | 747 | 2026-02-02 (+13 mo) |
| Pembrolizumab NCT05899049 |
P3 | Active, not recruiting | Carcinoma, Renal Cell | 251 | 2026-02-04 (-16 mo) |
| Pembrolizumab NCT04736706 |
P3 | Active, not recruiting | Carcinoma, Renal Cell | 1688 | 2026-02-04 (-9 mo) |
| Pembrolizumab (+) Berahyaluronidase alfa NCT06698042 |
P3 | Active, not recruiting | Lung Cancer; Non-Small Cell Lung Cancer | 67 | 2026-03-12 (-3 mo) |
| Tulisokibart NCT06956235 |
P2 | Active, not recruiting | Hidradenitis Suppurativa | 149 | 2026-04-02 (-7 mo) |
| Frespaciguat NCT05612035 |
P2 | Active, not recruiting | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | 129 | 2026-04-09 (+13 mo) |
| pembrolizumab NCT04895358 |
P3 | Active, not recruiting | Breast Neoplasms | 342 | 2026-04-24 (+24 mo) |
| IV Tulisokibart NCT06052059 |
P3 | Active, not recruiting | Ulcerative Colitis | 1109 | 2026-08-12 (-40 mo) |
| REJOICE-GI01 NCT06864169 |
P2 | Active, not recruiting | Gastrointestinal Cancer | 160 | 2026-08-18 (+1 mo) |
| Tulisokibart NCT07176390 |
P2 | Active, not recruiting | Arthritis, Rheumatoid | 185 | 2026-09-07 (-6 mo) |
| TroFuse-015 NCT06356311 |
P3 | Active, not recruiting | Gastroesophageal Cancer | 473 | 2026-10-19 (-3 mo) |
| Belzutifan NCT05239728 |
P3 | Active, not recruiting | Carcinoma, Renal Cell | 1800 | 2026-10-28 (-12 mo) |
| Pembrolizumab NCT04634877 |
P3 | Active, not recruiting | Endometrial Neoplasms | 990 | 2026-11-20 (+17 mo) |
| Belzutifan NCT05468697 |
P1/2 | Active, not recruiting | Renal Cell Carcinoma | 60 | 2026-12-22 (-3 mo) |
| Sacituzumab Govitecan NCT05609968 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 614 | 2027-01-12 |
| 9vHPV Vaccine NCT04199689 |
P3 | Active, not recruiting | Papillomavirus Infections | 6033 | 2027-01-15 (+13 mo) |
| Pembrolizumab NCT04241185 |
P3 | Active, not recruiting | Urinary Bladder Neoplasms | 520 | 2027-01-31 (+4 mo) |
| pembrolizumab NCT03407144 |
P2 | Active, not recruiting | Hodgkin Lymphoma | 340 | 2027-02-12 (+39 mo) |
| Tulisokibart NCT07486960 |
P2 | Active, not recruiting | Psoriatic Arthritis | 140 | 2027-02-17 |
| Pembrolizumab NCT04976634 |
P2 | Active, not recruiting | Neoplasm Malignant | 730 | 2027-03-22 (+8 mo) |
| Tulisokibart NCT07133633 |
P2 | Active, not recruiting | Radiographic Axial Spondyloarthritis | 315 | 2027-03-29 (-3 mo) |
| Posaconazole IV 6 mg/kg NCT04665037 |
P2 | Recruiting | Invasive Fungal Infection | 40 | 2027-03-31 (+44 mo) |
| Pembrolizumab NCT06305767 |
P1/2 | Active, not recruiting | Bladder Cancer | 230 | 2027-04-23 (+6 mo) |
| pembrolizumab NCT02628067 |
P2 | Active, not recruiting | Advanced Cancer; Anal Carcinoma | 1609 | 2027-05-04 (+109 mo) |
| Pembrolizumab NCT04380636 |
P3 | Active, not recruiting | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | 870 | 2027-05-05 (+10 mo) |
| Belzutifan NCT06428396 |
P2 | Active, not recruiting | Metastatic Breast Cancer | 120 | 2027-05-05 (-2 mo) |
| Sacituzumab tirumotecan NCT06074588 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer (NSCLC) | 556 | 2027-05-10 |
| Nemtabrutinib NCT05624554 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 300 | 2027-05-19 (+3 mo) |
| pembrolizumab NCT05173987 |
P3 | Active, not recruiting | Endometrial Neoplasms | 280 | 2027-05-27 (+10 mo) |
| Coformulated favezelimab/pembrolizumab NCT05845814 |
P1/2 | Active, not recruiting | Metastatic Urothelial Carcinoma; Urothelial Neoplasms | 390 | 2027-05-31 |
| MK-6916 NCT07862595 |
P2 | Recruiting | Pain Management | 380 | 2027-06-10 |
| Paclitaxel NCT05319730 |
P1/2 | Recruiting | Esophageal Squamous Cell Carcinoma | 230 | 2027-06-11 (+25 mo) |
| I-DXd NCT07405151 |
P1/2 | Recruiting | Oesophageal Squamous Cell Carcinoma | 60 | 2027-06-12 |
| Suvorexant NCT06655883 |
P3 | Recruiting | Insomnia | 300 | 2027-06-24 (+10 mo) |
| Sacituzumab tirumotecan NCT06312176 |
P3 | Recruiting | Breast Neoplasms | 1200 | 2027-07-11 |
| Bomedemstat NCT06079879 |
P3 | Active, not recruiting | Essential Thrombocythemia | 340 | 2027-07-14 (-13 mo) |
| MK-8527 NCT07044297 |
P3 | Active, not recruiting | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | 4390 | 2027-07-22 (-3 mo) |
| MK-3120 NCT07222488 |
P1/2 | Recruiting | Bladder Cancer; Urinary Bladder Neoplasms | 45 | 2027-07-30 (-19 mo) |
| ISL NCT06891066 |
P2 | Active, not recruiting | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | 150 | 2027-08-10 (-2 mo) |
| Zilovertamab vedotin NCT05139017 |
P2/3 | Recruiting | DLBCL; Diffuse Large B-Cell Lymphoma | 290 | 2027-09-24 (+33 mo) |
| Bomedemstat NCT06456346 |
P3 | Active, not recruiting | Essential Thrombocythemia | 300 | 2027-09-28 (-20 mo) |
| MK-7262 NCT07614984 |
P2 | Recruiting | Lipoprotein(a) | 750 | 2027-10-12 |
| MK-8527 NCT07071623 |
P3 | Recruiting | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | 4580 | 2027-10-18 (-3 mo) |
| MK-8690 NCT07895524 |
P2 | Not yet recruiting | Rheumatoid Arthritis | 60 | 2027-10-19 |
| Pembrolizumab 200 mg NCT02861573 |
P1/2 | Active, not recruiting | Metastatic Castration-Resistant Prostate Cancer | 1200 | 2027-10-22 (+92 mo) |
| Pembrolizumab 200 mg NCT04624204 |
P3 | Active, not recruiting | Small Cell Lung Cancer | 672 | 2027-10-28 |
| MK-8690 NCT07463183 |
P2 | Recruiting | Colitis Ulcerative; Ulcerative Colitis | 100 | 2027-10-28 |
| Opevesostat NCT06979596 |
P2 | Recruiting | Malignant Neoplasm | 250 | 2027-11-04 (-32 mo) |
| Enlicitide Decanoate NCT07821944 |
P3 | Recruiting | Hyperlipidemia; Hypercholesterolemia | 150 | 2027-11-26 |
| EXPrESSIVE-18 NCT07850609 |
P2 | Recruiting | HIV | 80 | 2027-12-02 |
| Zilovertamab vedotin NCT06890884 |
P2 | Recruiting | Lymphoma, Large B-Cell, Diffuse | 594 | 2027-12-13 |
| V503 NCT07785843 |
P3 | Recruiting | Papillomavirus Infections | 930 | 2027-12-18 |
| INTerpath-004 NCT06307431 |
P2 | Active, not recruiting | Renal Cell Carcinoma | 272 | 2028-01-08 |
| TroFuse-005 NCT06132958 |
P3 | Active, not recruiting | Endometrial Cancer | 710 | 2028-01-10 |
| Calderasib NCT06345729 |
P3 | Recruiting | Non-small Cell Lung Cancer | 348 | 2028-01-24 (-13 mo) |
| TroFuse-007 NCT06170788 |
P3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 614 | 2028-01-25 |
| Pembrolizumab NCT02332668 |
P1/2 | Recruiting | Melanoma; Lymphoma | 370 | 2028-02-02 |
| MK-3120 NCT06818643 |
P1/2 | Recruiting | Advanced Solid Tumors; Malignant Neoplasm | 270 | 2028-02-08 |
| Sacituzumab tirumotecan NCT06483334 |
P1/2 | Active, not recruiting | Metastatic Urothelial Carcinoma; Locally Advanced Urothelial Carcinoma | 38 | 2028-03-31 (-4 mo) |
| Pembrolizumab (+) Berahyaluronidase alfa NCT06041802 |
P2 | Active, not recruiting | Squamous Cell Carcinoma | 19 | 2028-03-31 (+13 mo) |
| V503 NCT03998254 |
P3 | Active, not recruiting | Papillomavirus Infections | 6000 | 2028-03-31 (+14 mo) |
| Ramucirumab NCT06445972 |
P1/2 | Recruiting | Gastroesophageal Junction; Gastroesophageal Adenocarcinoma | 210 | 2028-05-09 (+16 mo) |
| Opevesostat NCT06136650 |
P3 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | 1314 | 2028-05-10 (-31 mo) |
| Sacituzumab Tirumotecan NCT06459180 |
P3 | Active, not recruiting | Cervical Cancer | 686 | 2028-06-15 (-4 mo) |
| LIGHTRAY EXT NCT06925750 |
P2 | Active, not recruiting | Pulmonary Arterial Hypertension | 130 | 2028-06-16 (+9 mo) |
| Ifinatamab deruxtecan NCT06925737 |
P3 | Recruiting | Prostate Cancer; Prostatic Neoplasms | 1440 | 2028-06-26 |
| Intismeran autogene NCT06961006 |
P2 | Active, not recruiting | Malignant Melanoma | 160 | 2028-07-22 |
| Pembrolizumab NCT03711032 |
P3 | Active, not recruiting | High-risk Non-muscle Invasive Bladder Cancer | 1397 | 2028-07-31 (+74 mo) |
| Sacituzumab tirumotecan NCT06305754 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer (NSCLC) | 550 | 2028-08-17 |
| Pembrolizumab NCT05239741 |
P3 | Active, not recruiting | Colorectal Neoplasms | 100 | 2028-09-19 (+22 mo) |
| MOONBEAM NCT05587712 |
P2 | Recruiting | Pulmonary Arterial Hypertension | 42 | 2028-09-21 |
| MK-2010 NCT07793942 |
P2 | Recruiting | Malignant Neoplam; Advanced Solid Tumors | 480 | 2028-09-26 |
| Enlicitide Decanoate NCT06492291 |
P3 | Active, not recruiting | Hypercholesterolemia | 3000 | 2028-10-13 |
| IV Tulisokibart NCT06430801 |
P3 | Recruiting | Crohn's Disease | 1200 | 2028-10-30 (-10 mo) |
| MK-8748 NCT07705555 |
P3 | Recruiting | Diabetic Retinopathy; Macular Edema | 960 | 2028-10-31 |
| Pembrolizumab (+) Berahyaluronidase alfa NCT06504394 |
P2 | Active, not recruiting | Classical Hodgkin Lymphoma Recurrent; Classical Hodgkin Lymphoma Refractory | 66 | 2028-11-08 |
| Doravirine NCT04375800 |
P2 | Recruiting | Human Immunodeficiency Virus (HIV) Infection | 84 | 2028-11-12 (+43 mo) |
| OMAHA-003 NCT06136624 |
P3 | Recruiting | Prostate Cancer Metastatic | 1310 | 2028-11-30 (+5 mo) |
| MK-8748 NCT07705607 |
P3 | Recruiting | Diabetic Retinopathy; Macular Edema | 1104 | 2028-11-30 |
| Patritumab deruxtecan NCT06596694 |
P1/2 | Active, not recruiting | Gastrointestinal Cancer | 180 | 2028-12-07 (+4 mo) |
| SOTERIA NCT07218029 |
P3 | Active, not recruiting | Pulmonary Arterial Hypertension | 815 | 2028-12-07 |
| Nemtabrutinib NCT04728893 |
P2 | Recruiting | Hematologic Malignancies; Waldenstroms Macroglobulinaemia | 490 | 2029-01-04 (+18 mo) |
| Pembrolizumab NCT06422143 |
P3 | Recruiting | Non-small Cell Lung Cancer; NSCLC | 851 | 2029-01-12 |
| Opevesostat NCT06353386 |
P1/2 | Active, not recruiting | Prostatic Neoplasms, Castration-Resistant | 220 | 2029-01-15 (+10 mo) |
| ISL NCT07266831 |
P2/3 | Recruiting | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | 570 | 2029-02-01 |
| Gocatamig NCT06780137 |
P1/2 | Recruiting | Small Cell Lung Cancer | 327 | 2029-02-15 (+6 mo) |
| 9vHPV vaccine NCT05314023 |
P3 | Active, not recruiting | Genital Warts | 1590 | 2029-02-19 |
| Zilovertamab vedotin NCT05562830 |
P1/2 | Active, not recruiting | Urothelial Carcinoma | 48 | 2029-02-26 (+16 mo) |
| Raludotatug Deruxtecan NCT06843447 |
P1/2 | Recruiting | Ovarian Cancer Recurrent | 605 | 2029-03-27 |
| Calderasib NCT06997497 |
P3 | Recruiting | Colon Adenocarcinoma; Rectal Adenocarcinoma | 477 | 2029-03-28 (-5 mo) |
| Pembrolizumab NCT07302347 |
P1/2 | Recruiting | Malignant Neoplasm; Carcinoma, Merkel Cell | 20 | 2029-03-30 |
| Zilovertamab vedotin NCT06395103 |
P1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma | 90 | 2029-03-31 |
| MK-2750 NCT07876128 |
P1/2 | Not yet recruiting | Advanced Solid Tumors; Malignant Neoplasm | 300 | 2029-04-12 |
| waveLINE-007 NCT05406401 |
P2 | Active, not recruiting | Lymphoma, Large B-Cell, Diffuse (DLBCL) | 60 | 2029-04-26 |
| Sacituzumab tirumotecan NCT06824467 |
P3 | Recruiting | Ovarian Cancer; Fallopian Tube Cancer | 770 | 2029-04-27 (-11 mo) |
| ENHANCE-3 NCT07874815 |
P3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 2136 | 2029-04-29 |
| MK-2214 NCT07033494 |
P2 | Recruiting | Early Alzheimer's Disease | 340 | 2029-04-30 (-4 mo) |
| Zilovertamab vedotin NCT05458297 |
P2 | Active, not recruiting | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma | 189 | 2029-05-17 (+26 mo) |
| Sotatercept NCT07646860 |
P2 | Recruiting | Pulmonary Arterial Hypertension | 6 | 2029-05-24 |
| 9vHPV Vaccine NCT05285826 |
P3 | Active, not recruiting | Papillomavirus Infections | 8100 | 2029-05-25 (+54 mo) |
| MK-8591A NCT04776252 |
P3 | Active, not recruiting | HIV-1 Infection | 2000 | 2029-05-29 (+38 mo) |
| Tulisokibart NCT07861074 |
P2 | Recruiting | Noninfectious Intermediate, Posterior, or Panuveitis | 87 | 2029-06-05 |
| INTerpath-13 NCT07221474 |
P2 | Recruiting | Squamous Non-small Cell Lung Cancer | 180 | 2029-07-02 |
| Zilovertamab vedotin NCT06717347 |
P3 | Recruiting | Diffuse Large B-Cell Lymphoma | 1046 | 2029-07-02 (-33 mo) |
| TroFuse-031 NCT07419295 |
P3 | Recruiting | Bladder Cancer | 590 | 2029-07-27 |
| 9vHPV vaccine NCT05450705 |
P3 | Active, not recruiting | Papillomavirus Infections | 1500 | 2029-08-03 |
| MK-1084 NCT07286149 |
P1/2 | Recruiting | Lung Neoplasm Malignant | 140 | 2029-08-17 |
| Vericiguat tablet NCT05714085 |
P2/3 | Recruiting | Heart Failure; Left Ventricular Systolic Dysfunction | 342 | 2029-08-20 (-8 mo) |
| Pembrolizumab NCT06469944 |
P1/2 | Recruiting | Gastroesophageal Junction; Gastroesophageal Adenocarcinoma | 160 | 2029-09-12 (+32 mo) |
| DOR/ISL NCT07862569 |
P2 | Not yet recruiting | HIV-1; HIV Infection | 45 | 2029-09-24 |
| Tulisokibart NCT07867938 |
P2 | Recruiting | Pulmonary Sarcoidosis | 158 | 2029-10-05 |
| Sacituzumab tirumotecan NCT06428409 |
P1/2 | Recruiting | Colorectal Cancer; Pancreatic Ductal Adenocarcinoma | 220 | 2029-10-16 (+10 mo) |
| 9vHPV vaccine NCT04708041 |
P3 | Active, not recruiting | Papillomavirus Infections | 700 | 2029-10-23 (+4 mo) |
| Intismeran autogene NCT05933577 |
P3 | Active, not recruiting | Melanoma | 1089 | 2029-10-26 |
| MK-1084 NCT07252739 |
P2 | Recruiting | Malignant Neoplasm | 140 | 2029-11-15 |
| Enlicitide Decanoate NCT06008756 |
P3 | Active, not recruiting | Arteriosclerosis; Hypercholesterolaemia | 14550 | 2029-11-29 |
| Calderasib NCT07190248 |
P3 | Recruiting | Non-small Cell Lung Cancer | 675 | 2029-12-07 |
| coformulation pembrolizumab/quavonlimab NCT04938817 |
P1/2 | Active, not recruiting | Small Cell Lung Carcinoma | 110 | 2029-12-10 (+37 mo) |
| Patritumab deruxtecan NCT06797635 |
P2 | Recruiting | Breast Neoplasms; Breast Cancer | 372 | 2029-12-31 |
| CHORUS NCT07839585 |
P3 | Not yet recruiting | Pulmonary Hypertension | 352 | 2030-01-08 |
| Miransertib NCT04980872 |
P2 | Active, not recruiting | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | 60 | 2030-02-07 (+53 mo) |
| Sacituzumab tirumotecan NCT06841354 |
P3 | Recruiting | Triple Negative Breast Neoplasms | 1000 | 2030-05-18 |
| INTerpath-002 NCT06077760 |
P3 | Active, not recruiting | Non-small Cell Lung Cancer | 868 | 2030-06-25 |
| WaveSpan-008 NCT07519772 |
P1/2 | Recruiting | Lymphoma, Non-Hodgkin; Lymphoma, Follicular | 280 | 2030-07-01 |
| Belzutifan NCT07489495 |
P3 | Recruiting | Carcinoma, Renal Cell | 758 | 2030-11-27 |
| Gocatamig NCT07227597 |
P1/2 | Recruiting | Small Cell Lung Cancer Extensive Stage | 170 | 2030-11-29 |
| Pembrolizumab NCT06393374 |
P3 | Recruiting | Triple-Negative Breast Cancer | 1530 | 2030-12-16 |
| Patritumab Deruxtecan NCT06941272 |
P1/2 | Recruiting | Malignant Neoplasm | 50 | 2030-12-30 |
| Pembrolizumab (K) NCT03725059 |
P3 | Active, not recruiting | Breast Cancer | 1240 | 2031-01-24 |
| MOVe-NOW NCT06667700 |
P3 | Recruiting | Coronavirus Disease (COVID-19) | 3082 | 2031-01-26 |
| MK-3120 NCT07232602 |
P1/2 | Recruiting | Bladder Cancer | 55 | 2031-07-08 (+9 mo) |
| Ifinatamab Deruxtecan NCT07630974 |
P1/2 | Recruiting | Malignant Neoplasm | 134 | 2031-08-17 |
| R-DXd NCT07743164 |
P3 | Recruiting | Ovarian Cancer; Peritoneal Cancer | 646 | 2031-08-31 |
| Intismeran autogene NCT06833073 |
P2 | Recruiting | Urinary Bladder Neoplasms; Non-Muscle Invasive Bladder Neoplasms | 308 | 2031-09-03 |
| V181 NCT07013487 |
P3 | Active, not recruiting | Healthy | 12000 | 2031-09-06 (-5 mo) |
| MK-2010 NCT07785609 |
P2 | Recruiting | Advanced Solid Tumors; Malignant Neoplasm | 200 | 2031-09-30 |
| Docetaxel NCT06863272 |
P1/2 | Recruiting | Castration-Resistant Prostatic Cancer; Metastasis | 360 | 2031-10-01 (+19 mo) |
| Belzutifan NCT07049926 |
P1/2 | Recruiting | Renal Cell Carcinoma | 140 | 2031-10-26 |
| Pembrolizumab NCT07216703 |
P3 | Recruiting | Cervical Cancer | 1023 | 2031-10-29 |
| TroFuse-055 NCT07829783 |
P3 | Recruiting | Bladder Cancer | 400 | 2031-11-17 |
| Gocatamig NCT07908537 |
P3 | Not yet recruiting | Small Cell Lung Cancer | 564 | 2031-12-08 |
| Pembrolizumab NCT06780111 |
P1/2 | Recruiting | Esophageal Squamous Cell Carcinoma | 298 | 2032-01-04 (+10 mo) |
| Pembrolizumab (neoadjuvant) NCT06788912 |
P2 | Active, not recruiting | Lung Neoplasm Malignant | 60 | 2032-02-06 (+3 mo) |
| Pembrolizumab NCT04165070 |
P1/2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 450 | 2032-02-13 |
| LITESPARK-033 NCT07227402 |
P3 | Recruiting | Renal Cell Carcinoma | 904 | 2032-02-27 |
| R-DXD NCT06780098 |
P2 | Recruiting | Lung Neoplasm | 144 | 2032-03-02 (+18 mo) |
| Pembrolizumab NCT06731907 |
P2 | Recruiting | Non-small Cell Lung Cancer | 90 | 2032-03-12 |
| Raludotatug Deruxtecan NCT06780085 |
P2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 96 | 2032-03-12 (+18 mo) |
| R-DXd NCT07776691 |
P3 | Recruiting | Ovarian Cancer; Ovarian Neoplasms | 802 | 2032-03-19 |
| KANDLELIT-014 NCT07209111 |
P2 | Recruiting | Neoplasm Malignant | 150 | 2032-04-09 |
| TroFuse-033 NCT06952504 |
P3 | Recruiting | Endometrial Cancer | 1123 | 2032-05-24 |
| Nemtabrutinib NCT05947851 |
P3 | Recruiting | Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Chronic Lymphocytic | 735 | 2032-06-01 (-13 mo) |
| Bomedemstat NCT07722611 |
P2/3 | Recruiting | Polycythemia Vera | 380 | 2032-06-25 |
| TroFuse-01A NCT07908524 |
P1/2 | Not yet recruiting | Metastatic Castration-resistant Prostate Cancer | 290 | 2032-06-29 |
| MK-1045 NCT07634471 |
P2/3 | Recruiting | Follicular Lymphoma | 960 | 2032-07-23 |
| Patritumab deruxtecan NCT06686394 |
P1/2 | Recruiting | Breast Neoplasms; Breast Cancer | 181 | 2032-08-02 (+37 mo) |
| Nemtabrutinib NCT06136559 |
P3 | Recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 1200 | 2032-09-07 |
| Belzutifan NCT04924075 |
P2 | Recruiting | Pheochromocytoma/Paraganglioma; Pancreatic Neuroendocrine Tumor | 355 | 2032-11-18 (+92 mo) |
| Calderasib NCT07554339 |
P3 | Recruiting | Non-small Cell Lung Cancer | 310 | 2032-12-15 |
| TroFuse-021 NCT07318558 |
P3 | Recruiting | Ovarian Neoplasms; Ovarian Cancer | 900 | 2033-02-25 |
| Sacituzumab tirumotecan NCT06966700 |
P3 | Recruiting | Breast Neoplasms; Triple Negative Breast Neoplasms | 2400 | 2033-03-23 |
| Pembrolizumab NCT06623422 |
P3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 680 | 2033-05-16 |
| Patritumab deruxtecan NCT07060807 |
P3 | Recruiting | Breast Neoplasms | 1000 | 2033-07-14 |
| MK-1045 NCT07570173 |
P2/3 | Recruiting | B-cell Acute Lymphoblastic Leukemia | 340 | 2033-10-18 |
| MK-1045 NCT07709000 |
P2 | Recruiting | Chronic Lymphocytic Leukaemia; Small Lymphocytic Lymphoma | 60 | 2033-11-16 |
| Enlicitide Decanoate NCT07058077 |
P2/3 | Recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 153 | 2033-12-04 |
| Belzutifan NCT07700758 |
P2 | Recruiting | Malignant Neoplasm | 15 | 2034-01-02 |
| TroFuse-019 NCT06312137 |
P3 | Recruiting | Non Small Cell Lung Cancer | 780 | 2034-02-21 |
| Belzutifan NCT07405164 |
P3 | Recruiting | Von Hippel-Lindau Disease; Malignant Neoplasms | 450 | 2034-04-22 |
| INTerpath-014 NCT07513376 |
P3 | Recruiting | Non-small Cell Lung Cancer | 876 | 2034-08-22 |
| Bomedemstat NCT06351631 |
P3 | Recruiting | Thrombocythemia, Essential; Primary Myelofibrosis | 400 | 2034-12-04 |
| HARMONIZE NCT06814145 |
P2 | Active, not recruiting | Hypertension, Pulmonary | 440 | 2035-08-10 (+76 mo) |
| WaveSpan-010 NCT07917754 |
P2/3 | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma | 470 | 2037-03-13 |
| Tulisokibart NCT06651281 |
P3 | Recruiting | Crohn Disease; Colitis, Ulcerative | 1380 | 2037-12-17 |
| KANDLELIT-013 NCT07431827 |
P3 | Recruiting | Non-small Cell Lung Cancer | 400 | 2039-10-26 |
| Pembrolizumab NCT03486873 |
P3 | Recruiting | Solid Tumors; Hematologic Malignancies | 3500 | 2043-08-04 |